Benefits and harms of breast cancer screening: A systematic review

JAMA - Journal of the American Medical Association

Volumn 314, Issue 15, 2015, Pages 1615-1634

  Myers, Evan R ^a   Moorman, Patricia ^a,b   Gierisch, Jennifer M ^a,b,c   Havrilesky, Laura J ^a   Grimm, Lars J ^b   Ghate, Sujata ^b   Davidson, Brittany ^a   Mongtomery, Ranee Chatterjee ^a,b   Crowley, Matthew J ^a,b,c   McCrory, Douglas C ^a,b,c   Kendrick, Amy ^a   Sanders, Gillian D ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; BIOPSY TECHNIQUE; BREAST; BREAST CANCER; BREAST EXAMINATION; BREAST NEOPLASIA; BREAST SURGERY; CANADA; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER THERAPY; CASE CONTROL STUDY; COHORT ANALYSIS; FALSE POSITIVE RESULT; FAMILY HISTORY; FOLLOW UP; GENETIC SUSCEPTIBILITY; HEALTH HAZARD; HIGH RISK PATIENT; HUMAN; INTRADUCTAL CARCINOMA; LIFE EXPECTANCY; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERDIAGNOSIS; OVERTREATMENT; PEER REVIEW; POPULATION RESEARCH; PRIORITY JOURNAL; PROBABILITY; QUALITATIVE RESEARCH; QUALITY ADJUSTED LIFE EXPECTANCY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SIMULATION; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TOMOSYNTHESIS; TREATMENT DURATION; ULTRASOUND; UNITED STATES; ADULT; BIOPSY; BREAST TUMOR; EARLY DIAGNOSIS; ECHOGRAPHY; FEMALE; LABORATORY DIAGNOSIS; MIDDLE AGED; MORTALITY; PHYSICAL EXAMINATION; RISK; STANDARDS;

ADULT; BIOPSY; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; LIFE EXPECTANCY; MAMMOGRAPHY; MIDDLE AGED; PHYSICAL EXAMINATION; RISK;

EID: 84944627858     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.13183     Document Type: Review

References (131)

1. Berry DA, Cronin KA, Plevritis SK, et al; Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-1792.
2. Kerlikowske K, Grady D, Barclay J, Sickles EA, Eaton A, Ernster V. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA. 1993;270(20):2444-2450.
3. Brewer NT, Salz T, Lillie SE. Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med. 2007;146(7):502-510.
4. Valente SA, Levine GM, Silverstein MJ, et al. Accuracy of predicting axillary lymph node positivity by physical examination, mammography, ultrasonography, and magnetic resonance imaging. Ann Surg Oncol. 2012;19(6):1825-1830.
5. Brawley O, Byers T, Chen A, et al. New American Cancer Society process for creating trustworthy cancer screening guidelines. JAMA. 2011;306(22): 2495-2499.
6. Nelson HD, Tyne K, Naik A, et al. Screening for Breast Cancer: Systematic Evidence Review Update for the US Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2009. Evidence Review Update 74.
7. Oeffinger KC, Fontham ETH, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015. doi:10.1001/jama.2015.12783.
8. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380-382.
9. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;6:CD001877.
10. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L; U.S. Preventive Services Task Force. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(10):727-737, W237-42.
11. Fitzpatrick-Lewis D, Hodgson N, Ciliska D, Peirson L, Gauld M, Li YY; Canadian Task Force on Preventive Health Care. Breast Cancer Screening. Canadian Task Force on Preventive Health Care website. http://canadiantaskforce.ca/files/guidelines /2011-breast-cancer-systematic-review-en.pdf. 2011. Accessed December 19, 2013.
12. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M; Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108(11):2205-2240.
13. Broeders M, Moss S, Nyström L, et al; EUROSCREEN Working Group. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen. 2012;19(suppl 1):14-25.
14. Hofvind S, Ponti A, Patnick J, et al; EUNICE Project and Euroscreen Working Groups. False-positive results in mammographic screening for breast cancer in Europe: a literature review and survey of service screening programmes. J Med Screen. 2012;19(suppl 1):57-66.
15. Puliti D, Duffy SW, Miccinesi G, et al; EUROSCREEN Working Group. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen. 2012;19 (suppl 1):42-56.
16. National Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER∗Stat software version 8.1.5. http://www.seer.cancer.gov /seerstat. Accessed September 24, 2015.
17. Breen N, Gentleman JF, Schiller JS. Update on mammography trends: comparisons of rates in 2000, 2005, and 2008. Cancer. 2011;117(10):2209-2218.
18. Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med. 2011;155(8):481-492.
19. Welch HG, Passow HJ. Quantifying the benefits and harms of screening mammography. JAMA Intern Med. 2014;174(3):448-454.
20. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366.
21. Yen AM, Duffy SW, Chen TH, et al. Long-term incidence of breast cancer by trial arm in one county of the Swedish Two-County Trial of mammographic screening. Cancer. 2012;118(23): 5728-5732.
22. Johns LE, Moss SM; Age Trial Management Group. False-positive results in the randomized controlled trial of mammographic screening from age 40 ("Age" trial). Cancer Epidemiol Biomarkers Prev. 2010;19(11):2758-2764.
23. Andersson I, Janzon L. Reduced breast cancer mortality in women under age 50: updated results from the Malmö Mammographic Screening Program. J Natl Cancer Inst Monogr. 1997;(22):63-67.
24. Bjurstam N, Björneld L, Warwick J, et al. The Gothenburg Breast Screening Trial. Cancer. 2003; 97(10):2387-2396.
25. Alexander FE, Anderson TJ, Brown HK, et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet. 1999;353 (9168):1903-1908.
26. Frisell J, Lidbrink E. The Stockholm Mammographic Screening Trial: risks and benefits in age group 40-49 years. J Natl Cancer Inst Monogr. 1997;(22):49-51.
27. Shapiro S. Periodic screening for breast cancer: the HIP Randomized Controlled Trial. J Natl Cancer Inst Monogr. 1997;(22):27-30.
28. Mandelblatt JS, Cronin KA, Bailey S, et al; Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151(10): 738-747.
29. Kerlikowske K, Zhu W, Hubbard RA, et al; Breast Cancer Surveillance Consortium. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. JAMA Intern Med. 2013;173(9):807-816.
30. Braithwaite D, Zhu W, Hubbard RA, et al; Breast Cancer Surveillance Consortium. Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates? J Natl Cancer Inst. 2013;105(5):334-341.
31. Parvinen I, Chiu S, Pylkkänen L, et al. Effects of annual vs triennial mammography interval on breast cancer incidence and mortality in ages 40-49 in Finland. Br J Cancer. 2011;105(9):1388-1391.
32. Coldman AJ, Phillips N, Olivotto IA, Gordon P, Warren L, Kan L. Impact of changing from annual to biennial mammographic screening on breast cancer outcomes in women aged 50-79 in British Columbia. J Med Screen. 2008;15(4):182-187.
33. Blanchard K, Colbert JA, Kopans DB, et al. Long-term risk of false-positive screening results and subsequent biopsy as a function of mammography use. Radiology. 2006;240(2):335-342.
34. O'Meara ES, Zhu W, Hubbard RA, et al. Mammographic screening interval in relation to tumor characteristics and false-positive risk by race/ethnicity and age. Cancer. 2013;119(22):3959-3967.
35. Yankaskas BC, Taplin SH, Ichikawa L, et al. Association between mammography timing and measures of screening performance in the United States. Radiology. 2005;234(2):363-373.
36. Dittus K, Geller B, Weaver DL, et al; Breast Cancer Surveillance Consortium. Impact of mammography screening interval on breast cancer diagnosis by menopausal status and BMI. J Gen Intern Med. 2013;28(11):1454-1462.
37. Shapiro S. Evidence on screening for breast cancer from a randomized trial. Cancer. 1977;39(6) (suppl):2772-2782.
38. Sankaranarayanan R, Ramadas K, Thara S, et al. Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. J Natl Cancer Inst. 2011;103(19):1476-1480.
39. Abuidris DO, Elsheikh A, Ali M, et al. Breast-cancer screening with trained volunteers in a rural area of Sudan: a pilot study. Lancet Oncol. 2013;14(4):363-370.
40. Chiarelli AM, Majpruz V, Brown P, Thériault M, Shumak R, Mai V. The contribution of clinical breast examination to the accuracy of breast screening. J Natl Cancer Inst. 2009;101(18):1236-1243.
41. Honjo S, Ando J, Tsukioka T, et al. Relative and combined performance of mammography and ultrasonography for breast cancer screening in the general population: a pilot study in Tochigi Prefecture, Japan. Jpn J Clin Oncol. 2007;37(9):715-720.
42. Oestreicher N, Lehman CD, Seger DJ, Buist DS, White E. The incremental contribution of clinical breast examination to invasive cancer detection in a mammography screening program. AJR Am J Roentgenol. 2005;184(2):428-432.
43. Elmore JG, Reisch LM, Barton MB, et al. Efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst. 2005;97(14):1035-1043.
44. Fenton JJ, Barton MB, Geiger AM, et al. Screening clinical breast examination: how often does it miss lethal breast cancer? J Natl Cancer Inst Monogr. 2005;(35):67-71.
45. Nickson C, Mason KE, English DR, Kavanagh AM. Mammographic screening and breast cancer mortality: a case-control study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21(9):1479-1488.
46. Otto SJ, Fracheboud J, Verbeek AL, et al; National Evaluation Team for Breast Cancer Screening. Mammography screening and risk of breast cancer death: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2012;21(1):66-73.
47. van Schoor G, Moss SM, Otten JD, et al. Increasingly strong reduction in breast cancer mortality due to screening. Br J Cancer. 2011;104 (6):910-914.
48. Paap E, Holland R, den Heeten GJ, et al. A remarkable reduction of breast cancer deaths in screened versus unscreened women: a case-referent study. Cancer Causes Control. 2010; 21(10):1569-1573.
49. van Schoor G, Moss SM, Otten JD, et al. Effective biennial mammographic screening in women aged 40-49. Eur J Cancer. 2010;46(18): 3137-3140.
50. Allgood PC, Warwick J, Warren RM, Day NE, Duffy SW. A case-control study of the impact of the East Anglian breast screening programme on breast cancer mortality. Br J Cancer. 2008;98(1):206-209.
51. Puliti D, Miccinesi G, Collina N, et al; IMPACT Working Group. Effectiveness of service screening: a case-control study to assess breast cancer mortality reduction. Br J Cancer. 2008;99(3):423-427.
52. Roder D, Houssami N, Farshid G, et al. Population screening and intensity of screening are associated with reduced breast cancer mortality: evidence of efficacy of mammography screening in Australia. Breast Cancer Res Treat. 2008;108(3): 409-416.
53. Gabe R, Tryggvadóttir L, Sigfússon BF, Olafsdóttir GH, Sigurdsson K, Duffy SW. A case-control study to estimate the impact of the Icelandic population-based mammography screening program on breast cancer death. Acta Radiol. 2007;48(9):948-955.
54. Norman SA, Russell Localio A, Weber AL, et al. Protection of mammography screening against death from breast cancer in women aged 40-64 years. Cancer Causes Control. 2007;18(9):909-918.
55. Fielder HM, Warwick J, Brook D, et al. A case-control study to estimate the impact on breast cancer death of the breast screening programme in Wales. J Med Screen. 2004;11(4):194-198.
56. Broeders MJ, Verbeek AL, Straatman H, et al. Repeated mammographic screening reduces breast cancer mortality along the continuum of age. J Med Screen. 2002;9(4):163-167.
57. Weedon-Fekjær H, Romundstad PR, Vatten LJ. Modern mammography screening and breast cancer mortality: population study. BMJ. 2014;348: g3701.
58. Puliti D, Miccinesi G, Zappa M, Manneschi G, Crocetti E, Paci E. Balancing harms and benefits of service mammography screening programs: a cohort study. Breast Cancer Res. 2012;14(1):R9.
59. Hellquist BN, Duffy SW, Abdsaleh S, et al. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the Swedish Mammography Screening in Young Women (SCRY) cohort. Cancer. 2011;117(4):714-722.
60. Duffy SW, Tabar L, Olsen AH, et al. Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England [published correction appears in J Med Screen. 2010;17(2):106]. J Med Screen. 2010;17(1):25-30.
61. Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med. 2010;363(13):1203-1210.
62. Schonberg MA, Silliman RA, Marcantonio ER. Weighing the benefits and burdens of mammography screening among women age 80 years or older. J Clin Oncol. 2009;27(11):1774-1780.
63. Paci E, Coviello E, Miccinesi G, et al; IMPACT Working Group. Evaluation of service mammography screening impact in Italy: the contribution of hazard analysis. Eur J Cancer. 2008; 44(6):858-865.
64. Sarkeala T, Heinävaara S, Anttila A. Organised mammography screening reduces breast cancer mortality: a cohort study from Finland. Int J Cancer. 2008;122(3):614-619.
65. Jonsson H, Bordás P, Wallin H, Nyström L, Lenner P. Service screening with mammography in Northern Sweden: effects on breast cancer mortality-an update. J Med Screen. 2007;14(2):87-93.
66. Parvinen I, Helenius H, Pylkkänen L, et al. Service screening mammography reduces breast cancer mortality among elderly women in Turku. J Med Screen. 2006;13(1):34-40.
67. Swedish Organised Service Screening Evaluation Group. Reduction in breast cancer mortality from organized service screening with mammography, 1: further confirmation with extended data. Cancer Epidemiol Biomarkers Prev. 2006;15(1):45-51.
68. Vutuc C, Waldhoer T, Haidinger G. Breast cancer trends: opportunistic screening in Austria versus controlled screening in Finland and Sweden. Eur J Cancer Prev. 2006;15(4):343-346.
69. Olsen AH, Njor SH, Vejborg I, et al. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. BMJ. 2005;330(7485):220.
70. Jonsson H, Nyström L, Törnberg S, Lundgren B, Lenner P. Service screening with mammography: long-term effects on breast cancer mortality in the county of Gävleborg, Sweden. Breast. 2003;12(3): 183-193.
71. Jonsson H, Törnberg S, Nyström L, Lenner P. Service screening with mammography of women aged 70-74 years in Sweden: effects on breast cancer mortality. Cancer Detect Prev. 2003;27(5): 360-369.
72. Duffy SW, Tabár L, Chen HH, et al. The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer. 2002;95(3):458-469.
73. Paci E, Giorgi D, Bianchi S, et al. Assessment of the early impact of the population-based breast cancer screening programme in Florence (Italy) using mortality and surrogate measures. Eur J Cancer. 2002;38(4):568-573.
74. Tabár L, Vitak B, Chen HH, Yen MF, Duffy SW, Smith RA. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer. 2001; 91(9):1724-1731.
75. Jonsson H, Törnberg S, Nyström L, Lenner P. Service screening with mammography in Sweden-evaluation of effects of screening on breast cancer mortality in age group 40-49 years. Acta Oncol. 2000;39(5):617-623.
76. Moody-Ayers SY, Wells CK, Feinstein AR. "Benign" tumors and "early detection" in mammography-screened patients of a natural cohort with breast cancer. Arch Intern Med. 2000; 160(8):1109-1115.
77. Hakama M, Pukkala E, Heikkilä M, Kallio M. Effectiveness of the public health policy for breast cancer screening in Finland: population based cohort study. BMJ. 1997;314(7084):864-867.
78. Ascunce EN, Moreno-Iribas C, Barcos Urtiaga A, et al. Changes in breast cancer mortality in Navarre (Spain) after introduction of a screening programme. J Med Screen. 2007;14(1):14-20.
79. Plevritis SK, Sigal BM, Salzman P, Rosenberg J, Glynn P. A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. J Natl Cancer Inst Monogr. 2006;(36):86-95.
80. Mandelblatt JS, Schechter CB, Yabroff KR, et al; Breast Cancer in Older Women Research Consortium. Toward optimal screening strategies for older women: costs, benefits, and harms of breast cancer screening by age, biology, and health status. J Gen Intern Med. 2005;20(6):487-496.
81. Lansdorp-Vogelaar I, Gulati R, Mariotto AB, et al. Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med. 2014;161(2):104-112.
82. Etzioni R, Gulati R, Mallinger L, Mandelblatt J. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med. 2013;158(11):831-838.
83. de Gelder R, Heijnsdijk EA, van Ravesteyn NT, Fracheboud J, Draisma G, de Koning HJ. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev. 2011;33(1):111-121.
84. Biesheuvel C, Barratt A, Howard K, Houssami N, Irwig L. Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncol. 2007;8(12):1129-1138.
85. Coldman A, Phillips N. Incidence of breast cancer and estimates of overdiagnosis after the initiation of a population-based mammography screening program. CMAJ. 2013;185(10):E492-E498.
86. Lund E, Mode N, Waaseth M, Thalabard JC. Overdiagnosis of breast cancer in the Norwegian Breast Cancer Screening Program estimated by the Norwegian Women and Cancer cohort study. BMC Cancer. 2013;13:614.
87. Njor SH, Olsen AH, Blichert-Toft M, Schwartz W, Vejborg I, Lynge E. Overdiagnosis in screening mammography in Denmark: population based cohort study. BMJ. 2013;346:f1064.
88. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367(21):1998-2005.
89. Hofvind S, Lee CI, Elmore JG. Stage-specific breast cancer incidence rates among participants and non-participants of a population-based mammographic screening program. Breast Cancer Res Treat. 2012;135(1):291-299.
90. Zahl PH, Gøtzsche PC, Mæhlen J. Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. Lancet Oncol. 2011;12(12):1118-1124.
91. Morrell S, Barratt A, Irwig L, Howard K, Biesheuvel C, Armstrong B. Estimates of overdiagnosis of invasive breast cancer associated with screening mammography. Cancer Causes Control. 2010;21(2):275-282.
92. Jørgensen KJ, Zahl PH, Gøtzsche PC. Overdiagnosis in organised mammography screening in Denmark: a comparative study. BMC Womens Health. 2009;9:36.
93. Puliti D, Zappa M, Miccinesi G, Falini P, Crocetti E, Paci E. An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence. Eur J Cancer. 2009;45(18):3166-3171.
94. Olsen AH, Agbaje OF, Myles JP, Lynge E, Duffy SW. Overdiagnosis, sojourn time, and sensitivity in the Copenhagen mammography screening program. Breast J. 2006;12(4):338-342.
95. Paci E, Miccinesi G, Puliti D, et al. Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time: a service screening study in Italy. Breast Cancer Res. 2006;8(6):R68.
96. Jonsson H, Johansson R, Lenner P. Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. Int J Cancer. 2005;117 (5):842-847.
97. Paci E, Warwick J, Falini P, Duffy SW. Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern? J Med Screen. 2004;11(1):23-27.
98. Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ. 2004;328(7445):921-924.
99. Falk RS, Hofvind S, Skaane P, Haldorsen T. Overdiagnosis among women attending a population-based mammography screening program. Int J Cancer. 2013;133(3):705-712.
100. Hellquist BN, Duffy SW, Nyström L, Jonsson H. Overdiagnosis in the population-based service screening programme with mammography for women aged 40 to 49 years in Sweden. J Med Screen. 2012;19(1):14-19.
101. Lynge E, Ponti A, James T, et al; ICSN DCIS Working Group. Variation in detection of ductal carcinoma in situ during screening mammography: a survey within the International Cancer Screening Network. Eur J Cancer. 2014;50(1):185-192.
102. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002;94(20):1546-1554.
103. Kikuchi M, Tsunoda H, Koyama T, et al. Opportunistic breast cancer screening by mammography in Japan for women in their 40s at our preventive medical center: harm or benefit? Breast Cancer. 2014;21(2):135-139.
104. Ciatto S, Houssami N, Bernardi D, et al. Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. Lancet Oncol. 2013;14(7):583-589.
105. Domingo L, Jacobsen KK, von Euler-Chelpin M, et al. Seventeen-years overview of breast cancer inside and outside screening in Denmark. Acta Oncol. 2013;52(1):48-56.
106. Haas BM, Kalra V, Geisel J, Raghu M, Durand M, Philpotts LE. Comparison of tomosynthesis plus digital mammography and digital mammography alone for breast cancer screening. Radiology. 2013; 269(3):694-700.
107. Otten JD, Fracheboud J, den Heeten GJ, et al. Likelihood of early detection of breast cancer in relation to false-positive risk in life-time mammographic screening: population-based cohort study. Ann Oncol. 2013;24(10):2501-2506.
108. Skaane P, Bandos AI, Gullien R, et al. Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology. 2013;267(1):47-56.
109. Skaane P, Bandos AI, Gullien R, et al. Prospective trial comparing full-field digital mammography (FFDM) versus combined FFDM and tomosynthesis in a population-based screening programme using independent double reading with arbitration. Eur Radiol. 2013;23(8):2061-2071.
110. Tohno E, Umemoto T, Sasaki K, Morishima I, Ueno E. Effect of adding screening ultrasonography to screening mammography on patient recall and cancer detection rates: a retrospective study in Japan. Eur J Radiol. 2013;82(8):1227-1230.
111. Molins E, Comas M, Román R, et al. Effect of participation on the cumulative risk of false-positive recall in a breast cancer screening programme. Public Health. 2009;123(9):635-637.
112. Barton MB, Morley DS, Moore S, et al. Decreasing women's anxieties after abnormal mammograms: a controlled trial. J Natl Cancer Inst. 2004;96(7):529-538.
113. Ohlinger R, Heyer H, Thomas A, et al. Non-palpable breast lesions in asymptomatic women: diagnostic value of initial ultrasonography and comparison with mammography. Anticancer Res. 2006;26(5B):3943-3955.
114. Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG. Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst. 2006;98(11): 774-782.
115. Tosteson AN, Stout NK, Fryback DG, et al; DMIST Investigators. Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med. 2008;148(1):1-10.
116. van Ravesteyn NT, Miglioretti DL, Stout NK, et al. Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med. 2012;156(9):609-617.
117. Schousboe JT, Kerlikowske K, Loh A, Cummings SR. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med. 2011;155(1):10-20.
118. Stout NK, Lee SJ, Schechter CB, et al. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. J Natl Cancer Inst. 2014;106(6):dju092.
119. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making. 2006;26 (4):391-400.
120. de Haes JC, de Koning HJ, van Oortmarssen GJ, van Agt HM, de Bruyn AE, van Der Maas PJ. The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Cancer. 1991;49(4): 538-544.
121. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000;18(18):3302-3317.
122. Lidgren M, Wilking N, Jönsson B, Rehnberg C. Health related quality of life in different states of breast cancer. Qual Life Res. 2007;16(6):1073-1081.
123. Gierisch JM, Myers ER, Schmit KM, et al. Prioritization of research addressing management strategies for ductal carcinoma in situ. Ann Intern Med. 2014;160(7):484-491.
124. Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ [published online August 20, 2015]. JAMA Oncol. doi:2010.1001/jamaoncol .2015.2510.
125. Tosteson AN, Fryback DG, Hammond CS, et al. Consequences of false-positive screening mammograms. JAMA Intern Med. 2014;174(6):954-961.
126. Bansback N, Harrison M, Marra C. Does introducing imprecision around probabilities for benefit and harm influence the way people value treatments? [published online August 24, 2015]. Med Decis Making. doi:10.1177/0272989X15600708.
127. Hersch J, Barratt A, Jansen J, et al. Use of a decision aid including information on overdetection to support informed choice about breast cancer screening: a randomised controlled trial. Lancet. 2015;385(9978):1642-1652.
128. Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. Lancet Oncol. 2015;16(9):1123-1132.
129. Autier P, Boniol M, Smans M, Sullivan R, Boyle P. Statistical analyses in Swedish randomised trials on mammography screening and in other randomised trials on cancer screening: a systematic review [published online July 7, 2015]. J R Soc Med. doi:10.1177/0141076815593403.
130. Coldman A, Phillips N, Wilson C, et al. Pan-Canadian study of mammography screening and mortality from breast cancer. J Natl Cancer Inst. 2014;106(11):dju261.
131. Hamashima C, Ohta K, Kasahara Y, et al. A meta-analysis of mammographic screening with and without clinical breast examination. Cancer Sci. 2015;106(7):812-818.